Clinical trial
REAl World Evidence Of The Effectiveness And Clinical Practice Use Of Glecaprevir/Pibrentasvir For 8 Weeks Treatment In Patients With Chronic HepatitiS C GenotYpes 1 to 6 And Liver Cirrhosis In Russian Federation (EASY)
NCT04352309 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- REAl World Evidence Of The Effectiveness And Clinical Practice Use Of Glecaprevir/Pibrentasvir For 8 Weeks Treatment In Patients With Chronic HepatitiS C GenotYpes 1 to 6 And Liver Cirrhosis In Russian Federation (EASY)
- Lead sponsor
- AbbVie
- Phase
- Observational
- Overall status
- Completed
- Start date
- May 29, 2020
- Completion date
- June 11, 2021
- Enrollment
- 99 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
hepatitis c virus (hcv)